
Daniela Montagna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3129698/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Autoantibodies Against Proteins Previously Associated With Autoimmunity in Adult and Pediatric Patients With COVID-19 and Children With MIS-C. Frontiers in Immunology, 2022, 13, 841126.	2.2	18
2	Store-Operated Ca2+ Entry Is Up-Regulated in Tumour-Infiltrating Lymphocytes from Metastatic Colorectal Cancer Patients. Cancers, 2022, 14, 3312.	1.7	7
3	Cytokine-Induced Memory-Like NK Cells with High Reactivity against Acute Leukemia Blasts and Solid Tumor Cells Suitable for Adoptive Immunotherapy Approaches. Cancers, 2021, 13, 1577.	1.7	5
4	Human T cells engineered with a leukemia lipid-specific TCR enables donor-unrestricted recognition of CD1c-expressing leukemia. Nature Communications, 2021, 12, 4844.	5.8	3
5	Hydrogen Sulfide-Evoked Intracellular Ca2+ Signals in Primary Cultures of Metastatic Colorectal Cancer Cells. Cancers, 2020, 12, 3338.	1.7	15
6	Generation of donor-derived Wilms tumor antigen 1–specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study. Cytotherapy, 2019, 21, 958-972.	0.3	4
7	In Vitro Killing of Colorectal Carcinoma Cells by Autologous Activated NK Cells is Boosted by Anti-Epidermal Growth Factor Receptor-induced ADCC Regardless of RAS Mutation Status. Journal of Immunotherapy, 2018, 41, 190-200.	1.2	26
8	Stim and Orai mediate constitutive Ca2+ entry and control endoplasmic reticulum Ca2+ refilling in primary cultures of colorectal carcinoma cells. Oncotarget, 2018, 9, 31098-31119.	0.8	36
9	Different Polyubiquitinated Bodies in Human Dendritic Cells: IL-4 Causes PaCS During Differentiation while LPS or IFNα Induces DALIS During Maturation. Scientific Reports, 2017, 7, 1844.	1.6	7
10	Constitutive Store-Operated Ca ²⁺ Entry Leads to Enhanced Nitric Oxide Production and Proliferation in Infantile Hemangioma-Derived Endothelial Colony-Forming Cells. Stem Cells and Development, 2016, 25, 301-319.	1.1	51
11	In Vitro Efficient Expansion of Tumor Cells Deriving from Different Types of Human Tumor Samples. Medical Sciences (Basel, Switzerland), 2014, 2, 70-81.	1.3	9
12	Store-Operated Ca2+Entry Does Not Control Proliferation in Primary Cultures of Human Metastatic Renal Cellular Carcinoma. BioMed Research International, 2014, 2014, 1-19.	0.9	51
13	Hyper IgE syndrome: anaphylaxis in a patient carrying the N567DSTAT3mutation. Pediatric Allergy and Immunology, 2014, 25, 503-505.	1.1	9
14	A novel self-lipid antigen targets human T cells against CD1c+ leukemias. Journal of Experimental Medicine, 2014, 211, 1363-1377.	4.2	80
15	Discarded fraction from bone marrow erythrocyte depletion procedure is a good source of multipotent mesenchymal stromal cells. Cytotherapy, 2013, 15, 879-880.	0.3	0
16	Case Report: Long-Lasting Response in a Patient with Metastatic Renal Cell Cancer Receiving Antitumor Cytotoxic T Lymphocytes. Tumori, 2013, 99, e282-e284.	0.6	1
17	PaCS Is a Novel Cytoplasmic Structure Containing Functional Proteasome and Inducible by Cytokines/Trophic Factors. PLoS ONE, 2013, 8, e82560.	1.1	13
18	Case report: long-lasting response in a patient with metastatic renal cell cancer receiving antitumor cytotoxic T lymphocytes. Tumori, 2013, 99, 282e-4e.	0.6	0

DANIELA MONTAGNA

#	Article	IF	CITATIONS
19	Interleukin-27 Inhibits the Growth of Pediatric Acute Myeloid Leukemia in NOD/SCID/ <i>Il2rgâ^'/â^'</i> Mice. Clinical Cancer Research, 2012, 18, 1630-1640.	3.2	50
20	Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy, 2012, 14, 80-90.	0.3	29
21	Notch1 regulates chemotaxis and proliferation by controlling the CCâ€chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. Journal of Pathology, 2012, 226, 713-722.	2.1	54
22	Immunotherapeutic Intervention against Sarcomas. Journal of Cancer, 2011, 2, 350-356.	1.2	6
23	On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies. Clinical Immunology, 2011, 140, 152-159.	1.4	26
24	Invariant NKT Cell Reconstitution in Pediatric Leukemia Patients Given HLA-Haploidentical Stem Cell Transplantation Defines Distinct CD4+ and CD4â^ Subset Dynamics and Correlates with Remission State. Journal of Immunology, 2011, 186, 4490-4499.	0.4	85
25	Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunology Letters, 2010, 133, 99-105.	1.1	34
26	An Efficient Strategy to Induce and Maintain In Vitro Human T Cells Specific for Autologous Non-Small Cell Lung Carcinoma. PLoS ONE, 2010, 5, e12014.	1.1	3
27	Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood, 2009, 113, 3119-3129.	0.6	343
28	Donor/recipient mixed chimerism does not predict graft failure in children with Â-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling. Haematologica, 2008, 93, 1859-1867.	1.7	68
29	Interleukin-15 Favors the Expansion of Central Memory CD8+ T Cells in Ex Vivo Generated, Antileukemia Human Cytotoxic T Lymphocyte Lines. Journal of Immunotherapy, 2008, 31, 385-393.	1.2	23
30	Human Bone Marrow–Derived Mesenchymal Stem Cells Do Not Undergo Transformation after Long-term <i>In vitro</i> Culture and Do Not Exhibit Telomere Maintenance Mechanisms. Cancer Research, 2007, 67, 9142-9149.	0.4	649
31	Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood, 2007, 109, 5371-5379.	0.6	207
32	Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia. Blood, 2006, 108, 3843-3850.	0.6	45
33	Low percentages of circulating CD8+/CD45RA+ human T lymphocytes expressing β7 integrin correlate with the occurrence of intestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Experimental Hematology, 2006, 34, 1429-1434.	0.2	4
34	Single-Cell Cloning of Human, Donor-Derived Antileukemia T-Cell Lines for In vitro Separation of Graft-versus-Leukemia Effect from Graft-versus-Host Reaction. Cancer Research, 2006, 66, 7310-7316.	0.4	14
35	Bone marrow-resident memory T cells survive pretransplant chemotherapy and contribute to early immune reconstitution of patients with acute myeloid leukemia given mafosfamide-purged autologous bone marrow transplantation. Experimental Hematology, 2005, 33, 212-218.	0.2	14
36	Human Mesenchymal Stem Cells and Cyclosporin A Exert a Synergistic Suppressive Effect on In Vitro Activation of Alloantigen-Specific Cytotoxic Lymphocytes. Biology of Blood and Marrow Transplantation, 2005, 11, 1031-1032.	2.0	51

DANIELA MONTAGNA

#	Article	IF	CITATIONS
37	Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica, 2005, 90, 516-25.	1.7	444
38	Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling. International Journal of Cancer, 2004, 110, 76-86.	2.3	23
39	Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic stem cell transplantation. Best Practice and Research in Clinical Haematology, 2004, 17, 479-492.	0.7	8
40	T lymphocytes of recipient origin may contribute to the recovery of specific immune response toward viruses and fungi in children undergoing cord blood transplantation. Blood, 2004, 103, 4322-4329.	0.6	36
41	Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic stem cell transplantation. Best Practice and Research in Clinical Haematology, 2004, 17, 479-492.	0.7	6
42	Generation and ex vivo expansion of cytotoxic T lymphocytes directed toward different types of leukemia or myelodysplastic cells using both HLA-matched and partially matched donors. Experimental Hematology, 2003, 31, 1031-1038.	0.2	24
43	Infusion of autologous Epstein-Barr virus (EBV)–specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood, 2002, 99, 2592-2598.	0.6	230
44	Evaluation of infectious complications and immune recovery following high-dose chemotherapy (HDC) and autologous peripheral blood progenitor cell transplantation (PBPC-T) in 148 breast cancer patients. Anticancer Research, 2002, 22, 3701-8.	0.5	9
45	Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. Blood, 2001, 98, 3359-3366.	0.6	55
46	Neonatal invariant Vα24+ NKT lymphocytes are activated memory cells. European Journal of Immunology, 2000, 30, 1544-1550.	1.6	108
47	Depletion of Alloreactive T Cells by a Specific Anti–Interleukin-2 Receptor p55 Chain Immunotoxin Does Not Impair In Vitro Antileukemia and Antiviral Activity. Blood, 1999, 93, 3550-3557.	0.6	119
48	An improved PCR-heteroduplex method permits high-sensitivity detection of clonal expansions in complex T cell populations. Journal of Immunological Methods, 1996, 196, 181-192.	0.6	51
49	Frequency of donor cytotoxic T cell precursors does not correlate with occurrence of acute graft-versus-host disease in children transplanted using unrelated donors. Journal of Clinical Immunology, 1996, 16, 107-114.	2.0	11
50	natural killer cell activity in preterm infants: Effect of intravenous immune globulin administration. Journal of Pediatrics, 1990, 117, 465-466.	0.9	12
51	Acquired immune deficiency syndrome in childhood: Impaired production of interleukin-2 by HIV (LAV/HTLV III) infected patients. Infection, 1987, 15, 99-104.	2.3	10
52	Lymphocyte subpopulations in the neonate: A subset of HNK-1â^', OKT3â^', OKT8+ lymphocytes displays natural killer activity. Cellular Immunology, 1984, 85, 252-257.	1.4	27